Therapeutic vitamin D conjugates
First Claim
Patent Images
1. A carrier-drug conjugate, comprising a targeting group that is a non-hormonal vitamin D that is not hydroxylated at the carbon 1 position, conjugated at the carbon 3 position to a protein having apelin activity comprising an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:
- 1.
4 Assignments
0 Petitions
Accused Products
Abstract
The invention provides non-hormonal vitamin D conjugated to apelin proteins that result in increased absorption, bioavailability or circulating half-life when compared to non-conjugated forms. In some embodiments, the vitamin D targeting groups are coupled to the apelin proteins via the third carbon on the vitamin D backbone.
-
Citations
17 Claims
- 1. A carrier-drug conjugate, comprising a targeting group that is a non-hormonal vitamin D that is not hydroxylated at the carbon 1 position, conjugated at the carbon 3 position to a protein having apelin activity comprising an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:
- 3. A pharmaceutical composition comprising a carrier-drug conjugate comprising a targeting group that is a non-hormonal vitamin D that is not hydroxylated at the carbon 1 position, conjugated at the carbon 3 position via a scaffold to a protein having apelin activity comprising an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:
-
7. A pharmaceutical composition, comprising:
-
a) a protein having apelin activity comprising an amino acid sequence with at least a 90% sequence identity to SEQ ID NO;
1,b) a stably attached scaffold, c) a targeting group that is a non-hormonal vitamin D that is not hydroxylated at the carbon 1 position, conjugated at the carbon 3 position, wherein after administration to a first test subject, said protein has a half life measured by Enzyme Linked Immunosorbant Assay (ELISA) analysis of blood samples taken at a plurality of time points that is greater than a half life of said protein administered to a second test subject without said stably attached scaffold moiety and targeting group as measured by said ELISA analysis of blood samples taken at said plurality of time points. - View Dependent Claims (8, 9, 10, 11, 12)
-
- 13. A carrier-drug conjugate, comprising a targeting group that is vitamin D that is not hydroxylated at the carbon 1 position, non-releasably conjugated at the carbon 3 position to a protein having apelin activity comprising an amino acid sequence with at least a 90% sequence identity to SEQ ID NO:
Specification